The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…
BACKGROUND: Mesenteric fat is increasingly believed to exert an important influence on intestinal inflammation. A hallmark of severe Crohn's disease (CD) is the accumulation of mesenteric fat around the inflamed intestine, typically in the terminal ileum…
Genome-wide association studies revealed single nucleotide polymorphisms (SNPs) associated with inflammatory bowel disease (IBD) in coding regions of autophagy-related genes, such as _ATG16L1_ and _NOD2_…
Vedolizumab (VDZ) is a monoclonal antibody that targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC) and Crohn’s disease, its mode of action (MOA) remains unclear…
Background: Although the precise role of eosinophils in IBD is debated, elevated eosinophils may influence response to therapy and clinical outcomes1. Thus, therapeutic agents which affect both neutrophil and eosinophil recruitment may provide more robust clinical improvement in patients with UC…
Microscopic colitis (MC) is a chronic inflammatory condition of the colon, resulting in an impaired quality of life due to debilitating watery diarrhea. First-line therapy consists of budesonide, though a subset of patients is refractory or becomes budesonide- dependent…
INTRO/BACKGROUND Rigorous donor preselection on microbiota level, strict anaerobic processing, and repeated FMT administration were hypothesized to improve FMT outcomes for induction of remission in UC in the RESTORE-UC trial, for which we here report on the clinical results and observed microbial…
BACKGROUND: Neutrophil extracellular traps (NETs) consist of DNA filaments and cytoplasmic protein granules, extruded by neutrophils after PAD4-dependent activation…
Assessment of mucosal healing as a key denominator in the treat-to-target strategy for managing ulcerative colitis remains challenging. To address this, objective evaluation of histological disease activity holds promise…
SOCIETY: AGA With the expansion of IBD treatment options, there is increasingly the need for predictive models to determine which treatments work best for which patients with IBD…
This session will discuss novel findings in IBD genetics in different populations, including large scale exome sequencing and the effect of ancestry on the genetic make up in IBD…